Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

One of the biggest questions in ageing research is whether there is a ceiling on how long human beings can live. A recent study, published in Science, suggests there isn’t. The study measured the survival probabilities of 3,896 people in Italy aged 105 and older. It found that, while we are much more likely to die at 75 than at 55, once we reach about 105, the odds of death remain about the same each year of life.

This effect is often referred to as a “mortality plateau”. If it were impossible to live past a certain age, we would expect mortality rates to continue rising as people age, rather than plateau. The fact that the odds of dying don’t appear to increase past 105 suggests that we have not yet approached our maximum lifespan as a species. But is potentially living for over a century something we ought to look forward to? Here, philosophy can offer some important insights.

Read the full article on The Conversation website, written by Mackenzie Graham, Wellcome Centre for Ethics and Humanities. 

Oxford is a subscribing member of The ConversationFind out how you can write for The Conversation.

Similar stories

Prestigious award for Oxford professor's diabetes work

A University of Oxford professor has been awarded the 2021 EASD-Novo Nordisk Foundation Prize for Excellence for his decades of effort to understand, prevent and combat type 1 diabetes.

Wellcome accolades for Dr Douglas

Dr Alexander (Sandy) Douglas, an investigator at the Jenner Institute, Nuffield Department of Medicine, has recently received two prestigious Wellcome accolades.

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan (Department of Oncology) outlines the flagship work of the FOCUS4 trials, whose results were presented last weekend at the European Society of Medical Oncology (ESMO) annual meeting

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalisation or death from 14 days post the second dose vaccination, when substantial immunity should be expected.